|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017132,
umls-concept:C0021853,
umls-concept:C0030685,
umls-concept:C0035820,
umls-concept:C0061355,
umls-concept:C0391871,
umls-concept:C0521425,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1425983,
umls-concept:C1963578,
umls-concept:C1999177,
umls-concept:C2587213
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-4-22
|
|
pubmed:abstractText |
We recently showed that activation of G protein-coupled receptor 119 (GPR119) (also termed glucose dependent insulinotropic receptor) improves glucose homeostasis via direct cAMP-mediated enhancement of glucose-dependent insulin release in pancreatic beta-cells. Here we show that GPR119 also stimulates incretin hormone release and thus may regulate glucose homeostasis by this additional mechanism. GPR119 mRNA was found to be expressed at significant levels in intestinal subregions that produce glucose-dependent insulinotropic peptide and glucagon-like peptide (GLP)-1. Furthermore, in situ hybridization studies indicated that most GLP-1-producing cells coexpress GPR119 mRNA. In GLUTag cells, a well-established model of intestinal L-cell function, the potent GPR119 agonist AR231453 stimulated cAMP accumulation and GLP-1 release. When administered in mice, AR231453 increased active GLP-1 levels within 2 min after oral glucose delivery and substantially enhanced total glucose-dependent insulinotropic peptide levels. Blockade of GLP-1 receptor signaling with exendin(9-39) reduced the ability of AR231453 to improve glucose tolerance in mice. Conversely, combined administration of AR231453 and the DPP-4 inhibitor sitagliptin to wild-type mice significantly amplified both plasma GLP-1 levels and oral glucose tolerance, relative to either agent alone. In mice lacking GPR119, no such enhancement was seen. Thus, GPR119 regulates glucose tolerance by acting on intestinal endocrine cells as well as pancreatic beta-cells. These data also suggest that combined stimulation of incretin hormone release and protection against incretin hormone degradation may be an effective antidiabetic strategy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AR 231453,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl-Peptidase IV Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Gastric Inhibitory Polypeptide,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon-Like Peptide 1,
http://linkedlifedata.com/resource/pubmed/chemical/Gpr119 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Oxadiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, G-Protein-Coupled,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Glucagon,
http://linkedlifedata.com/resource/pubmed/chemical/glucagon-like peptide receptor
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0013-7227
|
|
pubmed:author |
pubmed-author:AlfonsoJeanJ,
pubmed-author:BagnolDidierD,
pubmed-author:BehanDominic PDP,
pubmed-author:CarrollChrisC,
pubmed-author:ChenRuopingR,
pubmed-author:ChuZhi-LiangZL,
pubmed-author:GutierrezVeronicaV,
pubmed-author:HeHongmeiH,
pubmed-author:JonesRobert MRM,
pubmed-author:LeonardJamesJ,
pubmed-author:LucmanAnnetteA,
pubmed-author:MondalaHelenH,
pubmed-author:PedrazaMelindaM,
pubmed-author:PunP PPP
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
149
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2038-47
|
|
pubmed:meshHeading |
pubmed-meshheading:18202141-Animals,
pubmed-meshheading:18202141-Blood Glucose,
pubmed-meshheading:18202141-Cells, Cultured,
pubmed-meshheading:18202141-Cyclic AMP,
pubmed-meshheading:18202141-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:18202141-Enteroendocrine Cells,
pubmed-meshheading:18202141-Gastric Inhibitory Polypeptide,
pubmed-meshheading:18202141-Glucagon-Like Peptide 1,
pubmed-meshheading:18202141-Glycemic Index,
pubmed-meshheading:18202141-Humans,
pubmed-meshheading:18202141-Insulin-Secreting Cells,
pubmed-meshheading:18202141-Male,
pubmed-meshheading:18202141-Mice,
pubmed-meshheading:18202141-Mice, Inbred C57BL,
pubmed-meshheading:18202141-Mice, Knockout,
pubmed-meshheading:18202141-Oxadiazoles,
pubmed-meshheading:18202141-Pyrimidines,
pubmed-meshheading:18202141-RNA, Messenger,
pubmed-meshheading:18202141-Receptors, G-Protein-Coupled,
pubmed-meshheading:18202141-Receptors, Glucagon,
pubmed-meshheading:18202141-Tissue Distribution
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
|
|
pubmed:affiliation |
Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San Diego, California 92121, USA.
|
|
pubmed:publicationType |
Journal Article
|
